ABSTRACT
Adenosine (ADO) is an endogenous inhibitory neuromodulator that limits cellular excitability in response to tissue trauma and inflammation. Adenosine kinase (AK; EC 2.7.1.20) is the primary metabolic enzyme regulating intra‐ and extracellular concentrations of ADO. AK inhibitors have been shown to significantly increase ADO concentrations at sites of tissue injury and to provide effective antinociceptive, antiinflammatory, and anticonvulsant activity in animal models. Structurally novel nucleoside and non‐nucleoside AK inhibitors that demonstrate high specificity for the AK enzyme compared with other ADO metabolic enzymes, transporters, and receptors have recently been synthesized. These compounds have also demonstrated improved cellular and tissue penetration compared with earlier tubercidin analogs. These compounds have been shown to exert beneficial effects in animal models of pain, inflammation and epilepsy with reduced cardiovascular side effects compared with direct acting ADO receptor (P1) agonists, thus supporting the hypothesis that AK inhibitors can enhance the actions of ADO in a site‐and event‐specific fashion.
Keywords: A‐134974, ABT‐702, Adenosine, Adenosine kinase, Analgesia, Inflammation, Epilepsy, P3269, P683
Full Text
The Full Text of this article is available as a PDF (248.9 KB).
References
- 1. Arch JRS, Newsholme EA. The control of the metabolism and the hormonal role of adenosine. Essays Biochem 1978;14:82–123. [PubMed] [Google Scholar]
- 2. Bennett LL, Hill DL. Structural requirements for activity of nucleosides as substrates for adenosine kinase: Orientation of substituents on the pentafuranosyl ring. Mol Pharmacol 1975;11:803–808. [PubMed] [Google Scholar]
- 3. Bennet LL, Allan PW, Hill DL. Metabolic studies with carbocyclic analogs of purine nucleosides. Mol Pharmacol 1968;4:208–217. [PubMed] [Google Scholar]
- 4. Berman RF, Cortese B, Wiesner JB. Anticonvulsant activity of an adenosine kinase inhibitor, GP 3269 against amygdala‐kindled seizures in rats. Soc Neurosci Abstr 1997;23:840.3. [Google Scholar]
- 5. Berman RF, Jarvis MF, Lupica CR. Adenosine involvement in kindled seizures. Kindling 1990;4:423–440. [Google Scholar]
- 6. Bhagwat S, Lee C‐H, Mckie J, Cowart MD, Grillot A‐L. 5,7‐disubstituted 4‐aminopyrido[2,3‐d]pyridopyridine compounds and their use as adenosine kinase inhibitors. 1998. WO9846605.
- 7. Bong GW, Rosengren S, Firestein GS. Spinal cord adenosine receptor stimulation in rats inhibits dermal neutrophil accumulation: The role of N‐methyl‐d‐aspartate receptors. J Clin Invest 1996;98:1–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Boyer SH, Erion MD, Ugarkar BG. C 4′ Modified adenosine kinase inhibitors. 1997. U.S. Patent No. 5,674,998.
- 9. Boyle DL, Kowaluk EA, Jarvis MF, et al. Anti‐inflammatory effects of ABT‐702, a novel adenosine kinase inhibitor in rat adjuvant arthritis. J Pharmacol Exp Ther 2001;296:495–500. [PubMed] [Google Scholar]
- 10. Britton DR, Mikusa J, Lee CH, Jarvis MF, Williams M, Kowaluk EA. Site and event specific increase of striatal adenosine release by adenosine kinase inhibition in rats. Neurosci Lett 1999;266:93–96. [DOI] [PubMed] [Google Scholar]
- 11. Browne CE, Ugarkar BG, Mullane KM, et al. Adenosine kinase inhibitors. 1999. U.S. Patent No. 5,864,033.
- 12. Burnstock G, Williams M. P2 Purinergic receptors: Modulation of cell function and therapeutic potential. J Pharmacol Exp Ther 2000;295:862–869. [PubMed] [Google Scholar]
- 13. Cottam HB, Wasson DB, Shih HC, Raychaudhuri A, Dipasquale G, Carson DA. New adenosine kinase inhibitors with oral antiflammatory activity: Synthesis and biological evaluation. J Med Chem 1993;36:3424–3430. [DOI] [PubMed] [Google Scholar]
- 14. Cowart M, Bennett MJ, Kerwin JF Jr. Synthesis of novel carbocyclic adenosine analogues as inhibitors of adenosine kinase. J Org Chem 1999;64:2240–2249. [Google Scholar]
- 15. Cowart M, Bhagwat SS. Heterocyclic substituted cyclopentane compounds. 1997. U.S. Patents No. 5,665,721 and No. 2000 6,143,749.
- 16. Cowart M, Lee C‐H, Gfesser GA, et al. Structure‐activity studies of 5‐substituted pyridopyrimidines as adenosine kinase inhibitors. Bioorg Med Chem Lett 2001;11:83–86. [DOI] [PubMed] [Google Scholar]
- 17. Cowart MC, Bennett M, Gfesser G, et al. SAR of a series of nucleoside analogs as adenosine kinase inhibitors. 213th ACS National Meeting ; April 1317, 2000; San Francisco , CA , USA .
- 18. Cronstein BN, Naime ED, Firestein G. The antiinflammatory effects of an adenosine kinase inhibitor are mediated by adenosine. Arth Rheum 1995;38:1040–1045. [DOI] [PubMed] [Google Scholar]
- 19. Davies LP, Jamieson DD, Baird‐Lambert JA, Kazlauskas R. Halogenated pyrrolopyrimidine analogues of adenosine from marine organisms: Pharmacological activities and potent inhibition of adenosine kinase. Biochem Pharmacol 1984;33:347–355. [DOI] [PubMed] [Google Scholar]
- 20. Dragunow M, Goddard GV, Laverty R. Is adenosine an endogenous anticonvulsant Epilepsia 1985;26:480–487. [DOI] [PubMed] [Google Scholar]
- 21. During MJ, Spencer DD. Adenosine: A potential mediator of seizure arrest and postictal refractoriness. Ann Neurol 1992;32:618–624. [DOI] [PubMed] [Google Scholar]
- 22. Elalaoui A, Divita G, Maury G, Imbach JL, Goody RD. Intrinsic tryptophan fluoresence of bovine liver adenosine kinase: Characterization of ligand binding sites and conformational changes. Eur J Biochem 1994;221:839–846. [DOI] [PubMed] [Google Scholar]
- 23. Engler RL. Consequences of activation and adenosine mediated inhibition of granulocytes during myocardial ischemia. Fed Proc 1987;46:2407–2412. [PubMed] [Google Scholar]
- 24. Erion MD, Wiesner JB, Dare J, Kopcho J, Ugarkar BG. Design, synthesis and anticonvulsant activity of the potent adenosine kinase inhibitor GP3269. Nucleosides Nucleotides 1997;16:1013–1021. [Google Scholar]
- 25. Erion MD, Wiesner, JB , Rosengren S, et al. Therapeutic potential of adenosine kinase inhibitors as analgesic agents. Drug Dev Res 2000;50:S14–06. [Google Scholar]
- 26. Evans MC, Swan JH, Meldrum BS. An adenosine analogue, 2‐chloroadenosine, protects against long term development of ischemic cell loss in the rat hippocampus. Neurosci Lett 1987;83:287–292. [DOI] [PubMed] [Google Scholar]
- 27. Fam SR, Gallagher CJ, Salter MW. P2Y1 purinoceptor‐mediated Ca2+ signaling and Ca2+ wave propagation in dorsal spinal cord astrocytes. J Neurosci 2000;20:2800–2808. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Firestein G, Boyle D, Bullough D, et al. Protective effect of an adenosine kinase inhibitor in septic shock. J Immunol 1994;152:5853–5859. [PubMed] [Google Scholar]
- 29. Firestein GS. Anti‐inflammatory effects of adenosine kinase inhibitors in acute and chronic inflammation. Drug Dev Res 1996;39:371–376. [Google Scholar]
- 30. Fredholm BB, Dunwiddie TV. How does adenosine inhibit transmitter release Trends Pharmacol Sci 1988;9:130–134. [DOI] [PubMed] [Google Scholar]
- 31. Goldberg MP, Monyer H, Weiss HH, Choi DW. Adenosine reduces cortical neuronal injury induced by oxygen and glucose deprivation in vitro. Neurosci Lett 1988;89:323–327. [DOI] [PubMed] [Google Scholar]
- 32. Golembiowska K, White TD, Sawynok J. Adenosine kinase inhibitors augument release of adenosine from spinal cord slices. Eur J Pharmacol 1996;307:157–162. [DOI] [PubMed] [Google Scholar]
- 33. Hajduk PJ, Gomstyan A, Didomenico S, et al. Design of adenosine kinase inhibitors from the NMR‐based screening of fragments. J Med Chem 2000;43:4781–4786. [DOI] [PubMed] [Google Scholar]
- 34. Hampton A. Substrate binding of adenine nucleosides and nucleotides to certain enzymes In: Townsend LB, ed. Chemistry of Nucleosides and Nucleotides. New York : Plenum, 1991:400–404. [Google Scholar]
- 35. Hawkins CF, Bagnara AS. Adenosine kinase from human erthrocytes: Kinetic studies and character ization of adenosine binding sites. Biochemistry 1987;26:1982–1987. [DOI] [PubMed] [Google Scholar]
- 36. Hinshaw BC, Gerster JF, Robins RK, Townsend LB. Pyrrolopyrimidine nucleosides. IV. Synthesis of certain 4,5‐disubstituted‐7‐(β‐d‐ribofuranosyl)pyrrolo[2,3‐d]pyrimidines related to the pyrrolo[2,3‐d]pyrimidine nucleoside antibiotics. J Heterocycl Chem 1969;6:215–221. [Google Scholar]
- 37. Holmgren M, Hedner J, Mellstrand T, Nordberg G, Hedner T. Characterization of the antinociceptive effects of some adenosine analogues in the rat. Naunyn Schmiedeberg's Arch Pharmacol 1986;334:290–293. [DOI] [PubMed] [Google Scholar]
- 38. Jarvis, MF , Yu H, Wismer C, et al. ABT‐702, a novel orally effective adenosine kinase (AK) inhibitor analgesic with anti‐inflammatory properties: I. In vitro characterization and acute antinociceptive effects in mice. J Pharmacol Exp Ther 2000;295:1156–1164. [PubMed] [Google Scholar]
- 39. Jiang N, Kowaluk EA, Lee C‐H, Mazdiyasni H, Chopp M. Adenosine kinase inhibition protects brain against transient focal ischemia in rats. Eur J Pharmacol 1997;320:131–137. [DOI] [PubMed] [Google Scholar]
- 40. Keil GJ, Delander GE. Spinally mediated antinociception is induced in mice by an adenosine kinase, but not an adenosine deaminase inhibitor. Life Sci 1992;51:171–176. [DOI] [PubMed] [Google Scholar]
- 41. Knutsen LJS, Murray TF. Adenosine and ATP in epilepsy In: Jacobson KA, Jarvis MF, Eds. Purinergic Approaches in Experimental Therapeutics. New York : Wiley‐Liss, 1997:423–224. [Google Scholar]
- 42. Kowaluk EA, Bhagwat SS, Jarvis MF. Adenosine kinase inhibitors. Curr Pharmaceut Des 1998;4:403–416. [PubMed] [Google Scholar]
- 43. Kowaluk EA, Kohlhaas K, Bannon A, Gunther K, Lynch JJ, Jarvis MF. Characterization of the effects of adenosine kinase inhibitors on acute thermal nociception in mice. Pharmacol Biochem Behav 1999;63:83–91. [DOI] [PubMed] [Google Scholar]
- 44. Kowaluk EA, Kohlhaas KL, Daanen J, Lee CH. Anticonvulsant effects of adenosine kinase inhibitors. Drug Dev Res 1996;37:190. [Google Scholar]
- 45. Kowaluk EA, Kohlhaas KL, Zhu C, et al. A‐134974, a novel adenosine kinase inhibitor with neuroprotective properties. Pharmacologist 1997;39:341. [Google Scholar]
- 46. Kowaluk EA, Wismer C, Mikusa J, et al. ABT‐702, a novel orally effective adenosine kinase (AK) in hibitor analgesic with anti‐inflammatory properties. II. Antinociceptive and anti‐inflammatory effects in rat models of persistent, inflammatory, and neuropathic pain. J Pharmacol Exp Ther 2000;295:1165–1174. [PubMed] [Google Scholar]
- 47. Lee C‐H, Jiang M, Cowart M, et al. Discovery of 4‐amino‐5‐(3‐bromophenyl)‐7‐(6‐morpholino‐pyridin‐3‐yl)pyrido[2,3‐d]pyrimidine, an orally active, non‐nucleoside adenosine kinase inhibitor. J Med Chem 2001;44:2133–2138. [DOI] [PubMed] [Google Scholar]
- 48. Lin BB, Hurley MC, Fox IH. Regulation of adenosine kinase by adenosine analogs. Mol Pharmacol 1988;34:501–505. [PubMed] [Google Scholar]
- 49. Lynch JJ, Alexander K, Jarvis MF, Kowaluk EA. Inhibition of adenosine kinase during oxygen‐glucose deprivation in rat cortical neuronal cultures. Neurosci Lett 1998;252:207–210. [DOI] [PubMed] [Google Scholar]
- 50. Lynch JJ, Jarvis MF, Kowaluk EA. An adenosine kinase inhibitor attenuates tactile allodynia in a rat model of diabetic neuropathic pain. Eur J Pharmacol 1999;364:141–146. [DOI] [PubMed] [Google Scholar]
- 51. Matthews IL, Erion MD, Ealick SE. Structure of human adenosine kinase at 1.5a resolution. Biochemistry 1998;10:15607–15620. [DOI] [PubMed] [Google Scholar]
- 52. McGaraughty S, Chu K, Wismer CT, et al. Effects of A‐134974, a novel adenosine kinase (AK) in hibitor, on carrageenan‐induced hyperalgesia and locomotor activity in rats: Evaluation of the sites of action. J Pharmacol Exp Ther 2001;296:501–509. [PubMed] [Google Scholar]
- 53. McNally T, Helfrich R, Cowart M, et al. Cloning and expression of the adenosine kinase gene from rat and human tissues. Biochem Biophys Res Comm 1997;231:645–650. [DOI] [PubMed] [Google Scholar]
- 54. Miller LP, Hsu C. Therapeutic potential for adenosine receptor activation in ischemic brain injury. J Neurotrauma 1992;9:S563–S577. [PubMed] [Google Scholar]
- 55. Miller LP, Jelovich LA, Yao L, Darae J, Ugarkar B, Foster AC. Pre‐ and peristroke treatment with the adenosine kinase inhibitor, 5′ deoxyiodotubercidin, significantly reduces infarct volume after tem porary occlusion of the middle cerebral artery in rats. Neurosci Lett 1996;220:73–76. [DOI] [PubMed] [Google Scholar]
- 56. Miller RL, Adamczyk DL, Miller WH, et al. Adenosine kinase from rabbit liver. II. Substrate and in hibitor specificity. J Biol Chem 1979;254:2346–2352. [PubMed] [Google Scholar]
- 57. Moser GH, Schrader J, Duessen A. Turnover of adenosine in plasma of human and dog blood. Am J Physiol 1989;25:C799–C806. [DOI] [PubMed] [Google Scholar]
- 58. Mullane K, Young M. Acadesine: Prototype adenosine regulating agent for treating myocardial ischemia‐reperfusion injury. Drug Dev Res 1993;23:336–343. [Google Scholar]
- 59. Newby AC, Holmquist AC, Illingworth J, Pearson JD. The control of adenosine concentration in polymorphonuclear leukocytes, cultured cells and isolated perfused heart form the rat. Biochem J 1983;214:317–323. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60. Newby AC. Adenosine and the concept of “retaliatory metabolites. Trends Biochem Sci 1984;2:42–44. [Google Scholar]
- 61. Onodera H, Sato G, Kogure K. Quantitative autoradiographic analysis of muscarinic, cholinergic, and adenosine A1 binding sites after transient forebrain ischemia in the gerbil. Brain Res 1987;415:309–322. [DOI] [PubMed] [Google Scholar]
- 62. Pak MA, Haas HL, Decking UKM, Schrader J. Inhibition of adenosine kinase increases endogenous adenosine and depresses neuronal activity in hippocampal slices. Neuropharmacology 1994;33:1049–1053. [DOI] [PubMed] [Google Scholar]
- 63. Patil S, Schneller SW, Hosoya M, Snoeck, et al. Synthesis and antiviral properties of (±)‐5′‐noraristeromycin and related purine carbocyclic nucleosides. J Med Chem 1992;35:3372. [DOI] [PubMed] [Google Scholar]
- 64. Phillis JW, Smith‐Barbour M. The adenosine kinase inhibitor, 5‐iodotubercidin, is not protective against cerebral ischemic injury in the gerbil. Life Sci 1993;53:497–502. [DOI] [PubMed] [Google Scholar]
- 65. Poon A, Sawynok J. Antinociception by adenosine analogs and an adenosine kinase inhibitor: De pendence on formalin concentration. Eur J Pharmacol 1995;286:177–184. [DOI] [PubMed] [Google Scholar]
- 66. Poon A, Sawynok J. Antinociception by adenosine analogs and inhibition of adenosine metabolism in an inflammatory thermal hyperalgesia model in the rat. Pain 1998;74:235–245. [DOI] [PubMed] [Google Scholar]
- 67. Rosengren S, Bong GW, Firestein GS. Anti‐inflammatory effects of an adenosine kinase inhibitor: Decrease neutrophil accumulation and vascular leakage. J Immunol 1995;154:5444–5451. [PubMed] [Google Scholar]
- 68. Sawynok J, Reid A, Poon A. Peripheral antinociceptive effect of an adenosine kinase inhibitor with augmentation by an adenosine deaminase inhibitor, in the rat formalin test. Pain 1998;74:75–81. [DOI] [PubMed] [Google Scholar]
- 69. Sollevi A. Adenosine for pain control. Acta Anesthesiol Scand 1997;110:135–136. [DOI] [PubMed] [Google Scholar]
- 70. Spychala J, Datta NS, Takabayashi K, et al. Cloning of human adenosine kinase cDNA: Sequence similarity to microbial ribokinases and fructokinases. Proc Natl Acad Sci USA 1996;93:1232–1237. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71. Suzuki R, Stanfa LC, Kowaluk EA, Williams M, Jarvis MF, Dickenson AH. The effect of ABT‐702, a novel adenosine kinase inhibitor, on the responses of spinal neurones following carrageenan inflammation and peripheral nerve injury. Br J Pharmacol 2001;132:1615–1623. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72. Tatlisumak T, Takano K, Carano RAD, Miller LP, Foster AC, Fisher M. Delayed treatment with an adenosine kinase inhibitor, GP 683, attenuates infarct size in rats with temporary middle cerebral artery occlusion. Stroke 1998;29:1952–1958. [DOI] [PubMed] [Google Scholar]
- 73. Ugarkar BG, Castellino AJ, Dare JM, et al. Adenosine kinase inhibitors. 2. Synthesis, enzyme inhibition, and antiseizure activity of diaryltubercidin analogues, J Med Chem 2000;43:2984–2905. [DOI] [PubMed] [Google Scholar]
- 74. Ugarkar BG, Dare JM, Kopcho JJ, et al. Adenosine kinase inhibitors. 1. Synthesis, enzyme inhibition, and antiseizure activity of 5‐iodotubercidin analogues. J Med Chem 2000;43:2883–2893. [DOI] [PubMed] [Google Scholar]
- 75. Von Lubitz DKJE. Adenosine and acute treatment of cerebral ischemia and stroke —“put out more flags” In: Jacobson KA, Jarvis MF, Eds. Purinergic Approaches in Experimental Therapeutics. New York : Wiley‐Liss, 1997:449–470. [Google Scholar]
- 76. Wang B, Rang J, White PF, et al. The effect of GP683, an adenosine kinase inhibitor, on the desflurane anesthetic requirement in dogs. Anesth Analges 1997;85:675–680. [DOI] [PubMed] [Google Scholar]
- 77. Wiesner JB, Ugarkar BG, Castellino AJ, et al. Adenosine kinase inhibitors as a novel approach to anticonvulsant therapy. J Pharmacol Exp Ther 1999;289:1669–1677. [PubMed] [Google Scholar]
- 78. Williams M, Jarvis MF. Purinergic and pyrimidinergic receptors as potential drug targets. Biochem Pharmacol 2000;59:1173–1185. [DOI] [PubMed] [Google Scholar]
- 79. Winn HR, Welsh JE, Rubio GR, Berne, RM. Changes in brain adenosine during bicuculline‐induced seizures in rats. Effects of hypoxia and altered systemic blood pressure. Circ Res 1980;47:568–577. [DOI] [PubMed] [Google Scholar]
- 80. Woolf CJ, Salter MW. Neuronal plasticity: Increasing the gain in pain. Science 2000;288:1765–1769. [DOI] [PubMed] [Google Scholar]
- 81. Zhang G, Franklin PH, Murray TF. Manipulation of endogenous adenosine in the rat prepiriform cortex modulates seizure susceptibility. J Pharmacol Exp Ther 1993;264:1415–1424. [PubMed] [Google Scholar]
- 82. Zhu CZ, Mikusa J, Chu K, et al. A‐134974, a novel adenosine kinase inhibitor, releives tactile allodynia via spinal sites of action in peripheral nerve injured rats. Brain Res 2001;905:104–110. [DOI] [PubMed] [Google Scholar]